Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States

Cancer

Volumn 122, Issue 16, 2016, Pages 2512-2523

  Ha, John ^a   Yan, Melissa ^a   Aguilar, Maria ^a   Bhuket, Taft ^a   Tana, Michele M ^b   Liu, Benny ^a   Gish, Robert G ^c,d   Wong, Robert J ^a  

^a HIGHLAND HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d HEPATITIS B FOUNDATION   (United States)

Author keywords

and End Results (SEER); Epidemiology; incidence; liver cancer; racial differences; screening; Surveillance

Indexed keywords

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; ASIAN; BLACK PERSON; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PATIENT; CANCER REGISTRY; CANCER SCREENING; CANCER SURVIVAL; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; HISPANIC; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RACE DIFFERENCE; UNITED STATES;

EID: 84982921368     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30103     Document Type: Article

References (34)

1. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
4. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127.
5. Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61:191–199.
6. Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014;109:542–553.
7. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60:1767–1775.
8. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555.
9. Surveillance, Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Research Data, Nov 2012 Sub (1973–2010) -Linked To County Attributes-Total US, 1969–2011 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2013.
10. Adamo M, Dickie L, Ruhl J. 2014 SEER Program Coding and Staging Manual. Bethesda, MD: National Cancer Institute; 2014.
11. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53:348–356.
12. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887.
13. Poordad F, Agarwal K, Younes Z, Cohen D, Xie W, Podsadecki T. Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study. Clin Infect Dis. 2015;60:608–610.
14. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–221.
15. Wong GL, Wong VW, Tan GM, et al. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int. 2008;28:79–87.
16. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336:1855–1859.
17. Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50:80–88.
18. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485–1491.
19. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–1273, e1261.
20. Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053–2063.
21. Centers for Disease Control and Prevention (CDC). Table 4. Reported cases of acute hepatitis C, by state—United States, 2007–2011. Available at: http://www.cdc.gov/hepatitis/Statistics/2011Surveillance/Table4.1.htm. Accessed July 21., 2015
22. Centers for Disease Control and Prevention (CDC). Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002–2009. MMRW Morb Mortal Wkly Rep. 2011;60:537–541.
23. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368:1859–1861.
24. Muir AJ, Naggie S. Hepatitis C virus treatment: is it possible to cure all hepatitis C virus patients? Clin Gastroenterol Hepatol. 2015;13:2166–2172.
25. Centers for Disease Control and Prevention (CDC). Notes from the field: hepatitis C virus infections among young adults—rural Wisconsin [serial online]. MMWR Morb Mortal Wkly Rep. 2012;61:358.
26. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61(RR-04):1–32.
27. Wong RJ, Corley DA. Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States. Dig Dis Sci. 2009;54:2031–2039.
28. Wong RJ, Devaki P, Nguyen L, Cheung R, Nguyen MH. Ethnic disparities and liver transplantation rates in hepatocellular carcinoma patients in the recent era: results from the Surveillance, Epidemiology, and End Results registry. Liver Transpl. 2014;20:528–535.
29. Artinyan A, Mailey B, Sanchez-Luege N, et al. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer. 2010;116:1367–1377.
30. Kao WY, Su CW, Chau GY, Lui WY, Wu CW, Wu JC. A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery. World J Surg. 2011;35:858–867.
31. Fiscella K, Franks P, Gold MR, Clancy CM. Inequality in quality: addressing socioeconomic, racial, and ethnic disparities in health care. JAMA. 2000;283:2579–2584.
32. Mathur AK, Osborne NH, Lynch RJ, Ghaferi AA, Dimick JB, Sonnenday CJ. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma. Arch Surg. 2010;145:1158–1163.
33. Wang J, Wang FW. Refusal of cancer-directed surgery strongly impairs survival of patients with localized hepatocellular carcinoma. Int J Surg Oncol 2010:381795, 2010.
34. Yu L, Sloane DA, Guo C, Howell CD. Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000. Clin Gastroenterol Hepatol. 2006;4:355–360.